These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 28198434)
41. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Webb TR; Joyner AS; Potter PM Drug Discov Today; 2013 Jan; 18(1-2):43-9. PubMed ID: 22885522 [TBL] [Abstract][Full Text] [Related]
43. The SF3B1 Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052 [TBL] [Abstract][Full Text] [Related]
44. The biological function and clinical significance of SF3B1 mutations in cancer. Zhou Z; Gong Q; Wang Y; Li M; Wang L; Ding H; Li P Biomark Res; 2020; 8():38. PubMed ID: 32905346 [TBL] [Abstract][Full Text] [Related]
45. Aberrant RNA splicing and therapeutic opportunities in cancers. Yamauchi H; Nishimura K; Yoshimi A Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550 [TBL] [Abstract][Full Text] [Related]
46. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564 [TBL] [Abstract][Full Text] [Related]
47. Spliceosomal disruption of the non-canonical BAF complex in cancer. Inoue D; Chew GL; Liu B; Michel BC; Pangallo J; D'Avino AR; Hitchman T; North K; Lee SC; Bitner L; Block A; Moore AR; Yoshimi A; Escobar-Hoyos L; Cho H; Penson A; Lu SX; Taylor J; Chen Y; Kadoch C; Abdel-Wahab O; Bradley RK Nature; 2019 Oct; 574(7778):432-436. PubMed ID: 31597964 [TBL] [Abstract][Full Text] [Related]
48. Characterization of the SF3B1-SUGP1 interface reveals how numerous cancer mutations cause mRNA missplicing. Zhang J; Xie J; Huang J; Liu X; Xu R; Tholen J; Galej WP; Tong L; Manley JL; Liu Z Genes Dev; 2023 Dec; 37(21-24):968-983. PubMed ID: 37977822 [TBL] [Abstract][Full Text] [Related]
49. Emerging roles of spliceosome in cancer and immunity. Yang H; Beutler B; Zhang D Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950 [TBL] [Abstract][Full Text] [Related]
50. In Silico Analysis of a Highly Mutated Gene in Cancer Provides Insight into Abnormal mRNA Splicing: Splicing Factor 3B Subunit 1 Samy A; Suzek BE; Ozdemir MK; Sensoy O Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32354150 [TBL] [Abstract][Full Text] [Related]
51. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. Darman RB; Seiler M; Agrawal AA; Lim KH; Peng S; Aird D; Bailey SL; Bhavsar EB; Chan B; Colla S; Corson L; Feala J; Fekkes P; Ichikawa K; Keaney GF; Lee L; Kumar P; Kunii K; MacKenzie C; Matijevic M; Mizui Y; Myint K; Park ES; Puyang X; Selvaraj A; Thomas MP; Tsai J; Wang JY; Warmuth M; Yang H; Zhu P; Garcia-Manero G; Furman RR; Yu L; Smith PG; Buonamici S Cell Rep; 2015 Nov; 13(5):1033-45. PubMed ID: 26565915 [TBL] [Abstract][Full Text] [Related]
52. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds. Cretu C; Agrawal AA; Cook A; Will CL; Fekkes P; Smith PG; Lührmann R; Larsen N; Buonamici S; Pena V Mol Cell; 2018 Apr; 70(2):265-273.e8. PubMed ID: 29656923 [TBL] [Abstract][Full Text] [Related]
53. The role of alternative splicing in cancer: From oncogenesis to drug resistance. Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093 [TBL] [Abstract][Full Text] [Related]
54. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation. Popli P; Richters MM; Chadchan SB; Kim TH; Tycksen E; Griffith O; Thaker PH; Griffith M; Kommagani R Cell Death Dis; 2020 Oct; 11(10):842. PubMed ID: 33040078 [TBL] [Abstract][Full Text] [Related]
55. Molecular Architecture of SF3b and Structural Consequences of Its Cancer-Related Mutations. Cretu C; Schmitzová J; Ponce-Salvatierra A; Dybkov O; De Laurentiis EI; Sharma K; Will CL; Urlaub H; Lührmann R; Pena V Mol Cell; 2016 Oct; 64(2):307-319. PubMed ID: 27720643 [TBL] [Abstract][Full Text] [Related]
56. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation. Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071 [TBL] [Abstract][Full Text] [Related]
59. [Screening of drugs that selectively inhibit uveal melanoma cells with SF3B1 mutations]. Luo X; Ren C; Liu X; Zhang G; Huang S; Yu L; Li Y Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1835-1842. PubMed ID: 35012916 [TBL] [Abstract][Full Text] [Related]